News

San Antonio biotech acquires U.K. wound-care company

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare ...

Kiromic founder says Houston biotech’s move to SA nearly a done deal

Houston-based immunotherapy company Kiromic is expected this month to approve moving its headquarters ...

Events

4th Annual SURF 2018

What: San Antonio Military Health System and Universities ResearchForum When: Thursday, June ...

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
News
BioBridge Global making investments for big-time growth
March 19, 2018

BioBridge Global CEO Martin Landon is working to leverage strong revenue increases in 2017 into more impressive long-term gains. GABE HERNANDEZ | SABJ

By W. Scott Bailey  – Senior Reporter, San Antonio Business Journal

BioBridge Global, a San Antonio-based biomedical company, has made multiple tactical changes and investments recently as demand for its products and services increased significantly over the last year, with revenue from its businesses eclipsing $170 million.

The collective revenue at BioBridge Global's three operating companies — the South Texas Blood & Tissue Center, QualTex Laboratories and GenCure — increased roughly 7 percent in 2017.

QualTex, one of the largest independent testing centers in the U.S. for blood and plasma products, accounted for about $110 million of the total revenue and is growing at roughly 10 percent per year, BioBridge CEO Martin Landon told me during an exclusive interview at the company’s Northwest Side campus.

BioBridge, which is entering a pivotal point in its evolution, recently installed a high-volume automated track at its Atlanta facility that is expected to dramatically improve the organization’s testing capabilities and capacity. It’s anticipated that the investment in Georgia will free up QualTex to expand its business opportunities at home.

Meanwhile, Landon is expecting GenCure's growth to help make 2018 an even stronger year for BioBridge. The parent company is spending about $3 million to develop a new biomanufacturing center in San Antonio that will enable GenCure to meet increasing demand in cellular therapy.

“There is a lot of clinical research going on, and we think we can support that research very well through our biomanufacturing center,” Landon said. “We believe that will lead to breakthroughs, and we want to be part of that.” 

BioBridge is making other changes to align its three businesses for more growth, including an organizational restructuring that Landon said will better integrate marketing and customer support operations.

BioBridge is also expanding its workforce. The company — which employs about 770 people, most of them in San Antonio — expects to exceed 800 employees by next year.

“We are bringing in a variety of resources,” Landon said. “We are bringing some new thought leaders to San Antonio — people with different experiences.”

Landon believes the collective investments, coupled with an expanding emphasis on collaboration with a growing list of partners locally and nationally, could elevate this city’s role in the biomedical industry.

“It’s an interesting time,” he said. “We all see an opportunity for San Antonio to be a leader.”

Stay informed. Subscribe to BioMed SA news alerts.